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Individual differences in the susceptibility to psychostimu-
lants have extensively been reported, both in humans (Jaffe
and Archer 1987; Ball et al. 1994; Gynther et al. 1995; van
den Bree et al. 1998) and in animals (Piazza et al. 1989,
2000; Mantsch et al. 2001). This study focused on two types
of rat that differ in their acute response to cocaine (COC).
These individuals are selected on the basis of their locomotor
response to a novel open-ﬁeld and, accordingly, labeled high
(HR) and low responders (LR) to novelty (Piazza et al. 1989,
1991b; Rouge-Pont et al. 1993; Dellu et al. 1996; Bevins
et al. 1997; Cools and Gingras 1998; Cools and Tuinstra
2003; Kabbaj 2004). Previous studies have demonstrated that
COC increases the locomotor response and the extracellular
levels of accumbal dopamine more strongly in HR than in
LR (Hooks et al. 1991b; Chefer et al. 2003).
Cocaine inhibits the re-uptake of monoamines by blocking
plasmalemmal monoamine transporters (Lee et al. 2001).
Several studies have suggested that individual differences in
the re-uptake of dopamine may explain individual differences
in the response to COC (Sabeti et al. 2002, 2003; Chefer
et al. 2003; Briegleb et al. 2004; Zahniser and Sorkin 2004).
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Abstract
Cocaine (COC) inhibits the re-uptake of dopamine. However,
the dopamine response to COC also depends on dopamine
inside storage vesicles. The aim of this study was to investi-
gate whether rats that differentially respond to COC differ in
their dopaminergic storage capacity of the nucleus accum-
bens. Total and vesicular levels of accumbal dopamine as
well as accumbal vesicular monoamine transporter-2 levels
were established in high (HR) and low responders (LR) to
novelty rats. Moreover, the effects of reserpine (RES) on the
COC-induced increase of extracellular accumbal dopamine
were investigated. HR displayed higher accumbal levels of
total and vesicular dopamine than LR. Moreover, HR dis-
played more accumbal vesicular monoamine transporters-2
than LR. COC increased extracellular accumbal dopamine
more strongly in HR than in LR. A low dose of RES prevented
the COC-induced increase of accumbal dopamine in LR, but
not in HR. A higher dose of RES was required to inhibit the
COC-induced increase of accumbal dopamine in HR. These
data demonstrate that HR were marked by a larger accumbal
dopaminergic storage pool than LR. It is hypothesized that
HR are more sensitive to COC than LR, because COC can
release more dopamine from accumbal storage vesicles in
HR than in LR.
Keywords: cocaine pharmacology, dopamine pools, individ-
ual differences, plasmalemmal transporters, reserpine phar-
macology, vesicular transporters.
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onstrated that the response to COC depends on storage
vesicles as well (Scheel-Kruger et al. 1977; McMillen et al.
1980; McMillen 1983; Davis 1985; Hurd and Ungerstedt
1989; Sulzer and Rayport 1990; Florin et al. 1995; Piﬂ et al.
1995; Venton et al. 2006). It is unknown to what extent
individual differences in the dopaminergic storage capacity
contribute to individual differences in response to COC. The
above-mentioned ﬁnding that HR are marked by a larger
COC-induced increase of accumbal dopamine than LR
suggests that HR store more accumbal dopamine inside
storage vesicles than LR. Accordingly, total and vesicular
levels of accumbal dopamine were measured in both types
of rat. Given that vesicular monoamine transporters-2
(VMAT-2) control the amount of dopamine inside storage
vesicles (Pothos et al. 2000; Pothos 2002), the levels of the
accumbal VMAT-2 were also measured. Based on the notion
that LR store less accumbal dopamine inside vesicles than
HR, it was hypothesized that the nucleus accumbens of LR
contains less VMAT than the nucleus accumbens of HR.
The drug reserpine (RES) inhibits the VMAT-mediated
uptake of cytoplasmatic monoamines into storage vesicles
(Kirshner et al. 1963; Henry et al. 1998). As the extracellular
levels of monoamines strongly depend on an intact shuttle
between cytoplasmatic and vesicular monoamines (Schoe-
maker and Nickolson 1983; Leviel et al. 1989; Arbuthnott
et al. 1990), RES decreases the extracellular levels of
accumbal dopamine (Verheij and Cools 2007). The present
study also investigated the effects of RES on the COC-
induced increase of extracellular accumbal dopamine. It was
hypothesized that COC-treated LR, which are supposed to be
marked by a relatively small storage pool containing low
amounts of VMAT, are more vulnerable to the RES-induced
dopamine depletion than COC-treated HR, which are
supposed to be marked by a relatively large storage pool
containing high amounts of VMAT.
Experimental procedures
See Appendix S1 for the full version of this section.
Open-ﬁeld selection
The open-ﬁeld selection is described by Cools et al. (1990).
Rats that habituated in less than 480 s and walked less than
4800 cm in 30 min were labeled LR. Rats that habituated after
840 s and walked more than 6000 cm in 30 min were labeled HR;
48 adult male LR and 59 adult male HR that were selected from
the outbred strain of Nijmegen Wistar rats were used throughout
this study.
Vesicular levels of accumbal dopamine (experiment 1)
The aim of this experiment was to measure the levels of vesicular
dopamine in punches of the nucleus accumbens. Seven days
after the open-ﬁeld selection, 10 LR and 10 HR were killed by
decapitation. Their brains were quickly removed, immediately
placed into a brain matrix, and subsequently sectioned at 3.0 mm
intervals (Mong et al. 2003). Coronal incisions were made at
anterior/posterior 9.0 and 12.0 mm (Paxinos and Watson 1986).
The most caudal incision was made at the position where the two
optic nerves fuse with the optic chiasm (Fig. 1). From the
identiﬁed slice, one punch of accumbal tissue was obtained from
either side of the brain using a 1.22 mm i.d. stainless steel needle
(Szczypka et al. 2001). The anterior commissure was used as a
landmark to reliable punch out accumbal tissue (Fig. 1). For each
rat, tissue of the left and right punch was pooled (total volume
2 · 3.5 mm
3 = 7.0 mm
3). The remaining tissue was ﬁxated in
p-formaldehyde solution in order to allow histological veriﬁcation
of the exact position of the punch needle. Puriﬁed accumbal
vesicles were prepared by ultracentrifugation (Staal et al. 2000).
Vesicular dopamine levels were obtained according to the
procedures described by Sandoval et al. (2003). The ﬁnal
supernatant was injected into a high performance liquid
chromatography–electrochemical detection system for separation
and quantiﬁcation of vesicular dopamine. Vesicular dopamine
levels were normalized for variation in protein loading using
the total protein concentration of the ﬁrst supernatant (Sandoval
et al. 2003).
Fig. 1 Representative placement of accumbal punches. The brain
was placed in a brain matrix. The ﬁrst incision was made at the po-
sition where the two optic nerves fuse with the optic chiasm. The
second incision was made 3 mm rostral to this point. Coronal incisions
were similar to anterior/posterior 9.0 and 12.0 mm of Paxinos and
Watson (1986). The anterior commissure was used as a landmark to
reliable punch out accumbal tissue. For each rat, tissue of the left and
right punch was pooled. Correctly placed punches were located within
the area of the black oval.
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(experiment 2)
To investigate whether the putative individual differences in
accumbal dopaminergic storage capacity were associated with
individual differences in VMAT-2 levels, accumbal punches of 12
LR and 12 HR (isolated as described above) were analyzed for
VMAT-2 expression. The punches were homogenized in phosphate-
buffered saline containing urea, sodium dodecyl sulfate, b-mercap-
toethanol, phenylmethylsulfonyl ﬂuoride, and soybean trypsin
inhibitor (Jensen et al. 1998). Next, proteins were separated on an
8% sodium dodecyl sulfate–polyacrylamide gel and transferred to
nitrocellulose membranes. VMAT-2 expression was examined using
the anti-VMAT-2 antibody (1 : 1000, AB1767; Chemicon, Hamp-
shire, UK) and anti-b-tubulin antibody (1 : 3000, E7; Chu and
Klymkowsky 1989). Band intensities were corrected for background.
For quantiﬁcation of the total levels of accumbal dopamine, the
samples that were used to asses the amount of VMAT were diluted
and immediately injected into the high performance liquid
chromatography–electrochemical detection system. VMAT and total
dopamine levels were normalized for variation in protein loading
using the levels of tubulin (Hedtjarn et al. 2002).
Effects of reserpine on the cocaine-induced increase of
extracellular accumbal dopamine (experiment 3)
The aim of this experiment was to investigate the effects of RES
on the COC-induced increase of extracellular accumbal dopamine.
A group of 26 LR and 37 HR were unilaterally implanted with a
guide cannula directed at the right nucleus accumbens according to
previously described procedures (Verheij and Cools 2007). The rats
were allowed to recover from surgery for the next 7–10 days in
dialysis cages. At the ﬁrst day of the experiment, a dialysis probe
was inserted into the guide cannula. Four hours following probe
insertion, HR and LR were injected with RES or its solvent (see
below). At the second day of the experiment, accumbal dialysates
were analyzed for dopamine according to previously described
procedures (De Leonibus et al. 2006). As soon as the dopamine
samples differed less than 10%, three baseline samples were taken.
The average of these three samples served as control value (100%)
to study the drug-induced changes of accumbal dopamine. Imme-
diately after the third baseline sample was taken, rats that were
treated with RES or its solvent on day 1 were injected with COC or
saline (see below). These rats were subsequently exposed to a cage
that was slightly larger than their home cage and lacked sawdust on
the ﬂoor (Verheij and Cools 2007). After this exposure to novelty,
the accumbal extracellular concentration of dopamine was recorded
(at 5 min intervals) for a period of 90 min.
Both LR and HR were injected with 1 mg/kg of RES on day 1 and
15 mg/kg of COC on day 2. Because 1 mg/kg of RES had no effect
on the COC-induced increase of accumbal dopamine in HR, a new
groupofHRwaspre-treatedwith2 mg/kgofRESonday1.Alldrugs
were given i.p. in a volume of 1 mL/kg. At the end of the micro-
dialysis experiments, rats were given an overdose of pentobarbital
and were intracardially perfused with p-formaldehyde. Vibratome
sections were cut to verify the location of the microdialysis probe.
Analysis of the data (experiments 1–3)
Data were statistically analyzed using an ANOVA with the factor type
of rat (experiments 1 and 2) or the factors type of rat, treatment, and
time (experiment 3). In case HR and LR were differentially sensitive
to COC, the effects of RES on the effects of COC were statistically
analyzed per type of rat. The relationship between the mean COC-
induced increase of accumbal extracellular dopamine and the
response to novelty on the open-ﬁeld (traveled distance and
habituation time) were evaluated by mean of Pearson’s two-tailed
correlation analysis. All data were expressed as mean ± SEM. A
probability level of p < 0.05 was taken as signiﬁcant in every test.
Results
Open-ﬁeld selection
The open-ﬁeld selection procedure revealed 24% LR and
30% HR. The average distance traveled in 30 min was
3493 ± 191 and 8643 ± 373 cm in LR and HR, respectively.
The average habituation time was 324 ± 28 s in LR and
1340 ± 66 s in HR. Rats that did not fulﬁll the criteria (46%)
were not included in this study.
Vesicular levels of accumbal dopamine (experiment 1)
Histological veriﬁcation revealed that three LR and three HR
had to be excluded because incorrect placement of the punch
needle. Figure 1 shows the coronal region of the nucleus
accumbens in which all correctly placed punches were
located.
The vesicular levels of accumbal dopamine are depicted in
Fig. 2 (LR: n = 9 and HR: n = 9). The nucleus accumbens of
LR was marked by smaller levels of dopamine inside storage
vesicles than the nucleus accumbens of HR [Fig. 2a; one-
way ANOVA: type effect F(1,16) = 6.100, p = 0.025]. The
accumbal levels of general protein were equal in LR and HR
[Fig. 2b; one-way ANOVA: type effect: n.s.], demonstrating
that similar pieces of tissue were punched from the nucleus
accumbens of both types of rat.
Accumbal VMAT-2 levels and total levels of accumbal
dopamine (experiment 2)
The accumbal VMAT-2 immunoreactivity levels are depicted
in Fig. 3 (LR: n = 10 and HR: n = 10). The anti-VMAT-2
antibody labeled both a relatively small protein of 70 kDa
and a relatively large protein of 110 kDa (Fig. 3a; Yao
et al. 2004; Yao and Hersh 2007). A one-way ANOVA
revealed that the levels of both the small and the large
VMAT-2 protein were signiﬁcant less in the nucleus
accumbens of LR than of HR [Fig. 3b; (VMAT-2
70 kDa): type-effect: F(1,18) = 6.490, p = 0.020; Fig. 3c
(VMAT-2 110 kDa): type effect: F(1,18) = 6.822, p =
0.018]. The antibody raised against the loading control
tubulin selectively labeled a protein of 50 kDa (Fig. 3a;
Kong et al. 1999). The accumbal tubulin levels were equal in
LR and HR (Fig. 3d; one-way ANOVA: type effect: n.s.),
demonstrating that similar pieces of tissue were punched
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et al. 2002). The total levels of accumbal dopamine are
depicted in Fig. 4 (LR: n = 10 and HR: n = 10). The total
levels of dopamine were signiﬁcant less in the nucleus
accumbens of LR than in the nucleus accumbens of HR
[Fig. 4; one-way ANOVA: type-effect: F(1,18) = 6.000, p =
0.023].
Effects of reserpine on the cocaine-induced increase of
extracellular accumbal dopamine (experiment 3)
The dialysis probes of the present study were located in the
same region of the nucleus accumbens as the dialysis probes
of a previous study (see Fig. 2 of Verheij and Cools 2007).
Histological veriﬁcation revealed that two HR and two LR
had to be excluded because of incorrect placement of the
dialysis probe. One additional HR had to be excluded from
analysis because of obstruction of the microdialysis probe.
The baseline absolute concentration of extracellular
accumbal dopamine was 0.68 ± 0.11 pg/10 lLi nL R
(mean ± SEM of rats belonging to the pooled groups of
solvent-treated LR: n = 8 + 8 = 16) and 0.84 ± 0.15 pg/
10 lL in HR (mean ± SEM of rats belonging to the pooled
groups of solvent-treated HR: n = 9 + 8 = 17). Extracellu-
lar dopamine levels after RES were 0.58 ± 0.07 pg/10 lL
in LR (1 mg/kg: n = 8) and 0.31 ± 0.05 pg/10 lLi nH R
(1 and 2 mg/kg pooled: n = 8 + 9 = 17). The RES-induced
decrease of the basal levels of dopamine in LR [100% –
(0.58/0.68 pg) = 15%] and HR [100% – (0.31/0.84 pg] =
63%) are very similar to the previously reported RES-
induced decrease of the basal levels of dopamine in these
rats (Verheij and Cools 2007). No rat had to be excluded
because of undetectable dopamine levels.
The effects of saline (=solvent of COC) on the extracel-
lular amount of accumbal dopamine in novelty-challenged
LR and HR are depicted in Fig. 5 (LR saline: n = 8 and
HR saline: n = 9). The accumbal dopamine response to
novelty was larger in saline-treated HR than in saline-
treated LR [Fig. 5; two-way ANOVA: type · time effect: n.s;
type effect: F(1,15) = 12.733, p = 0.003]. One sample t-test
revealed that the extracellular levels of dopamine signiﬁ-
cantly increased from baseline at 16 out of the 18 time
points in control HR, whereas the extracellular levels of
dopamine did not differ from baseline at any time point in
control LR (Fig. 5).
The effects of 15 mg/kg of COC on the extracellular
amount of accumbal dopamine in novelty-challenged rats
are depicted in Fig. 6a (LR COC: n = 8 and HR COC:
n = 8]. COC increased the extracellular dopamine levels in
both HR [Fig. 6a; two-way ANOVA: treat · time effect:
F(18,270) = 11.832, p < 0.001] and LR [Fig. 6a; two-way
ANOVA: treat · time effect: F(18,252) = 5.163, p < 0.001].
However, the COC-induced increase of dopamine was
stronger in HR than in LR [Fig. 6a; three-way ANOVA:
type · treat · time effect: F(18,522) = 2.889, p < 0.001].
Accumbal dopamine levels increased during the ﬁrst
70 min in COC-treated HR (Fig. 6a; Student’s t-test),
whereas accumbal dopamine levels increased only during
the ﬁrst 25 min in COC-treated LR (Fig. 6a; Student’s t-
test). Pearson’s analysis revealed that both traveled distance
and habituation time on the open-ﬁeld positively correlated
with the mean COC-induced increase of accumbal extra-
cellular dopamine [Fig. 6b; LR and HR pooled (n = 16):
distance (left): R = 0.553, p = 0.02; habituation time
(right): R = 0.572, p = 0.02].
The effects of 1 mg/kg of RES on the COC-induced
increase of extracellular accumbal dopamine are depicted in
Fig. 7 (LR: RES 1 mg/kg + COC: n = 8 and HR: RES
1 mg/kg + COC: n = 8). The dose of 1 mg/kg of RES
strongly reduced the COC-induced increase of extracellular
dopamine in LR [Fig. 7a; two-way ANOVA: treat · time
effect: F(18,252) = 5.263, p < 0.001]. In fact, one sample t-test
revealed that accumbal dopamine did not anymore increase
from baseline at any time point in these rats (Fig. 7a). The
dose of 1 mg/kg of RES did not at all affect the COC-
(a)
(b)
Fig. 2 (a) Vesicular levels of accumbal dopamine. The amount of
vesicular dopamine (pg) was determined in punches of accumbal tis-
sue. Vesicular dopamine levels were normalized against the protein
levels of supernatant 1. *Signiﬁcant difference between LR (n = 9) and
HR (n = 9) rats (one-way ANOVA). (b) Accumbal protein levels. The
total levels of general protein of supernatant 1 did not differ between
LR (n = 9) and HR (n = 9). n.s, no signiﬁcant differences (one-way
ANOVA). All data were expressed as mean ± SEM.
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[Fig. 7b; two-way ANOVA: treat · time effect: n.s; treat effect:
n.s.]. One sample t-test revealed that accumbal dopamine
signiﬁcantly increased from baseline in HR during the ﬁrst
65 min (Fig. 7b).
The effects of 2 mg/kg of RES on the extracellular amount
of accumbal dopamine in COC-treated HR are also depicted
in Fig. 7 (HR: RES 2 mg/kg + COC: n = 9). A two-way
ANOVA revealed that the effects of RES were dose-dependent
[Fig. 7b; dose · time effect: F(36,396) = 3.135, p < 0.001].
The dose of 2 mg/kg of RES strongly reduced the COC-
induced increase of accumbal dopamine in HR [Fig. 7b; two-
way ANOVA: treat · time effect: F(18,270) = 8.272, p < 0.001].
One sample t-test revealed that dopamine signiﬁcantly
increased from baseline only during the ﬁrst 35 min
[Fig. 7b].
Discussion
Accumbal levels of vesicular dopamine and VMAT-2
(experiments 1 + 2)
Low responders to novelty displayed smaller amounts of
dopamine inside the storage vesicles of the nucleus accum-
bens than HR (see Fig. 2). These results can be explained by
the ﬁnding that LR had less accumbal VMAT-2 than HR (see
Fig. 3). It must be noted that two VMAT-2 proteins of
different molecular size were identiﬁed. It has previously
been shown that VMAT-2 proteins are expressed in two
morphological distinct types of storage vesicles (Nirenberg
et al. 1995, 1996, 1997). The small molecular size of VMAT-
2( 70 kDa) has been found to be localized on small
synaptic vesicles, whereas the large molecular size of VMAT-
(a)
(c)
(b)
(d)
Fig. 3 (a) Representative western blots of one LR (left) and one HR
(right) using anti b-tubulin and anti vesicular monoamine transporter-2
(VMAT-2) antibodies. Western blot analysis was performed on pun-
ches of accumbal tissue. One band for tubulin and two bands for
VMAT-2 were observed. (b–c) Immunoreactivity levels of the relatively
small accumbal VMAT-2 protein of 70 kDa and the relatively large
accumbal VMAT-2 protein of 110 kDa in LR and HR. VMAT-2 levels
were quantiﬁed using tubulin for normalization. *Signiﬁcant differences
between LR (n = 10) and HR (n = 10) rats (one-way ANOVA). (d)
Immunoreactivity levels of the accumbal tubulin protein in LR and HR.
Tubulin levels did not differ between LR (n = 10) and HR (n = 10). n.s,
no signiﬁcant differences (one-way ANOVA). All data were expressed as
mean ± SEM.
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core vesicles, depending on the glycosylation of the protein
(Yao et al. 2004; Yao and Hersh 2007). The present ﬁnding
that LR displayed lower levels of both types of VMAT-2 than
HR, indicates that LR are marked by smaller amounts of
accumbal dopamine in both small and large vesicles than
HR. These smaller levels of vesicular dopamine in LR than
in HR may well account for the ﬁnding that the total levels of
dopamine were smaller in LR than in HR (see Fig. 4).
Effects of reserpine on cocaine-induced accumbal
dopamine levels (experiment 3)
Cocaine increased the extracellular accumbal dopamine
levels more strongly in HR than in LR (see Fig. 6a). These
results in novelty-challenged rats are very similar to the
previous reported results in non-novelty-challenged rats
(Hooks et al. 1991b; Chefer et al. 2003). In fact, the
dopamine increase after novelty hardly contributed to the
dopamine increase after COC (see Fig. 6a). It was also
demonstrated that both behavioral criteria to select HR and
LR on the open-ﬁeld (traveled distance and habituation time)
positively correlated with the COC-induced increase of
accumbal dopamine (see Fig. 6b). These data were in
agreement with the previously reported notion that the
response to novelty can predict the individual-speciﬁc
response to drugs of abuse (Piazza et al. 1989, 1991a;
Hooks et al. 1991a,b; Cools and Gingras 1998). The
relatively low dose of 1 mg/kg of RES reduced the COC-
induced increase of extracellular accumbal dopamine in LR,
but not in HR (see Fig. 7). A higher dose of 2 mg/kg of RES
was required to inhibit the COC-induced increase of
accumbal dopamine in HR (see Fig. 7). These data conﬁrm
the hypothesis that COC-treated LR are more vulnerable to
the RES-induced dopamine depletion than COC-treated HR.
Noradrenaline and serotonin are both known to control the
release of dopamine (Kilpatrick et al. 1996; Cools and
Tuinstra 2003). Because RES ultimately depletes dopamine,
noradrenaline, and serotonin, the observed effects of RES
may be the result of drug-induced changes in the levels of
Fig. 4 Total levels of accumbal dopamine. The total amount of
dopamine (pg) was determined in punches of accumbal tissue.
Dopamine levels were quantiﬁed using tubulin for normalization
(Fig. 3d). *Signiﬁcant difference between LR (n = 10) and HR (n = 10)
rats (one-way ANOVA). All data were expressed as mean ± SEM.
Fig. 5 Effects of novelty (new cage) on the extracellular levels of
dopamine in the nucleus accumbens in reserpine-solvent and saline-
treated LR (circles) and reserpine-solvent and saline-treated HR
(squares). Reserpine-solvent (1 mL/kg, i.p.) was administered 24 h
before saline (1 mL/kg, i.p.). Rats (LR: n = 8 and HR: n = 9) were
exposed to novelty immediately after the saline injection. Accumbal
dopamine levels after novelty are expressed as percentage of baseline
accumbal dopamine levels. The horizontal line represents basal
dopamine levels (=100%).
#Signiﬁcant increase relative to baseline
(one sample t-test). All data were expressed as mean ± SEM.
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vesicular levels of dopamine differed between LR and HR,
suggests that the observed individual differences in the
effects of RES are, most likely, because of individual
differences in the RES-induced decrease of the levels of
dopamine inside storage vesicles.
One could argue that RES reduced the dopamine response
to COC for the reason that RES diminished the basal levels
of dopamine. Under the condition that COC blocks the re-
uptake of neurotransmitters, low basal levels of extracellular
dopamine result in a reduced COC-induced increase of
dopamine. This explanation, however, is not supported by
(a) 
(b)
Fig. 6 (a) Effects of 15 mg/kg of cocaine on the extracellular levels of
dopamine in the nucleus accumbens of novelty-challenged LR (cir-
cles) and novelty-challenged HR (squares). Accumbal dopamine lev-
els after cocaine (ﬁlled, LR: n = 8 and HR: n = 8) or saline (open, LR:
n = 8 and HR: n = 9) are expressed as percentage of baseline ac-
cumbal dopamine levels.
#Signiﬁcant increase relative to saline (Stu-
dent’s t-test). All data were expressed as mean ± SEM. (b) Correlation
of traveled distance (left)/habituation time (right) on the open-ﬁeld and
accumbal dopamine increase after cocaine. Traveled distance is ex-
pressed as locomotor activity (cm) during 30 min on the open-ﬁeld.
Habituation time is expressed as the duration of the period (s) that
started as soon as the rat began to explore the open-ﬁeld and ended
as soon as the locomotor activity stopped for at least 90 s. Accumbal
dopamine levels are expressed as mean increase from baseline dur-
ing 90 min after cocaine [LR (circles): n = 8 and HR (squares): n = 8].
The dotted lines represent the regression based ﬁt line ± the predic-
tion interval at a conﬁdence level of 95%. One single dot represents
one single rat.
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reduced the basal levels of dopamine (reduction 63%), the
dopamine increase following COC was not inhibited at all
(Fig. 7). Moreover, in LR, in which 1 mg/kg of RES only
slightly reduced the basal levels of dopamine (reduction
15%), the dopamine increase following COC was completely
inhibited (Fig. 7). The fact that the results in RES-treated rats
cannot exclusively be explained by the generally accepted
mode of action that COC inhibits dopamine re-uptake
implies that COC must have an additional mode of action.
The ﬁnding that RES reduced the extracellular dopamine
increase to COC (Fig. 7) indicates that COC facilitates the
release of dopamine that is derived from storage vesicles
(Sulzer and Rayport 1990).
Dopamine-releasing action of cocaine
The present data were in agreement with previously reported
data demonstrating that the COC-induced release of dopa-
mine is caused by exocytosis (Carboni et al. 1989; Yan 2003;
Venton et al. 2006) and not by the reversal of plasmalemmal
transporters (Fischer and Cho 1979; Butcher et al. 1988;
Sulzer et al. 1993; Piﬂ et al. 1995; Scarponi et al. 1999).
The exact mechanism of action for COC to release dopamine
from vesicles is currently unknown. Superfusion studies have
demonstrated that the dopamine and noradrenaline-releasing
action of COC depends not only on storage pools, but also
requires the inhibition of plasmalemmal transporters (Piﬂ
et al. 1995, 1999). These data indicate that the COC-induced
inhibition of dopamine transporters (DATs), somehow,
promotes the dopamine release from vesicles. The notion
that both DATs and dopaminergic storage vesicles are
involved in the effects of COC in animals is conﬁrmed by
the outcome of studies in humans demonstrating that the
chronic use of COC produces changes not only in DAT-
binding, but also in VMAT-binding (Wilson et al. 1996;
Little et al. 1999, 2003).
A dopamine-releasing action of COC involves that
dopaminergic storage vesicles become empty after this drug
(Pothos and Sulzer 1998; Pothos 2002). Under the condition
that COC depletes dopaminergic storage vesicles, replenish-
ment of these vesicles is required. In fact, it has recently been
demonstrated that stimulation of D1 and D2 receptors
promotes the reﬁll of vesicles after dopamine has been
released by transporter blockers like COC (Brown et al.
2001a,b; Sandoval et al. 2002). Given the observed individ-
ual differences in COC-induced dopamine release, this D1/
D2-receptor mediated reﬁll of vesicles is expected to be
larger in COC-treated HR than in COC-treated LR. This
nicely ﬁts in with the ﬁnding that HR express more VMAT
than LR.
Effects of novelty on accumbal dopamine levels
The ﬁnding that HR that were exposed to saline and novelty
were marked by a larger increase of extracellular accumbal
dopamine than LR that were exposed to saline and novelty
(see Fig. 5) ﬁts in with the available literature reporting that
challenged HR are marked by a larger accumbal dopamine
response than challenged LR (Piazza et al. 1991b; Rouge-
Pont et al. 1993; Saigusa et al. 1999; Verheij and Cools
(a)
(b)
Fig. 7 Effects of 1 and 2 mg/kg of reserpine (RES) on the cocaine-
induced increase of accumbal extracellular dopamine levels in novelty-
challenged LR (a) and novelty-challenged HR (b). Cocaine-induced
accumbal dopamine levels in rats treated with solvent (LR: n = 8 and
HR: n = 8) or RES (1 mg/kg: LR: n = 8 and HR: n = 8; 2 mg/kg: HR:
n = 9) are expressed as percentage of baseline accumbal dopamine
levels. The horizontal line represents basal dopamine levels (=100%).
RES reduced baseline levels of dopamine in LR [solvent vs. RES
(1 mg/kg): reduction: 100% – (0.58/0.68 pg) = 15%] and HR [solvent
vs. RES (1 and 2 mg/kg pooled): reduction: 100% – (0.31/
0.84 pg) = 63%].
#Signiﬁcant dopamine increase after RES (one
sample t-test). All data were expressed as mean ± SEM.
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dopamine did not at all increase in novelty-challenged LR is
not in agreement with a previous study (Verheij and Cools
2007). It is important to note that the saline-treated and
novelty-challenged rats of the present study were also treated
with RES-solvent (see Experimental procedures). It has been
shown that repeated exposure to the same stressor reduces, or
even prevents, the stress-induced increase of dopamine in the
nucleus accumbens (Imperato et al. 1992, 1993; Cabib and
Puglisi-Allegra 1996a,b). Accordingly, the most likely
explanation for the present ﬁnding that accumbal dopamine
levels did not increase in novelty-challenged LR is that the
rats of the present study were stressed twice by a systemic
injection (RES solvent on day 1 and saline on day 2),
whereas the rats of the previous study were stressed only
once (RES solvent on day 1 and no saline on day 2). The
previously reported ﬁnding that RES blocked the accumbal
dopamine increase in novelty-challenged LR (Verheij and
Cools 2007), suggest that the long-term processes that are
triggered by multiple exposure to stressors (anticipation/
adaptation) might be related to dopamine stored in RES-
sensitive vesicles. The fact that RES did not at all inhibit the
accumbal dopamine increase in novelty-challenged HR
(Verheij and Cools 2007) may explain why the dopamine
decreasing effects of repeated exposure to injection stress did
not occur in these rats.
It has previously been reported that RES strongly reduces
the baseline levels of dopamine in HR, but not LR (Verheij
and Cools 2007). As discussed above, RES strongly reduces
the dopamine response to novelty in LR, but not HR. The
present study shows that RES decreased the dopamine
response to COC in both types of rat. It is, therefore,
suggested that the individual differences in (i) the basal
dopamine response, (ii) the dopamine response to novelty,
and (iii) the dopamine response to COC are regulated by
three distinct neuronal substrates (for details see Verheij and
Cools 2008).
Conclusion
The results of the present study indicate that the search for
individual differences in the susceptibility to COC should
focus not only on individual differences in the re-uptake
mechanisms of dopamine, but also on individual differences
in the capacity to store dopamine inside vesicles. The present
data give rise to the conclusion that LR contain less
dopamine inside accumbal storage vesicles than HR because
the nucleus accumbens of LR display lower levels VMAT-2
than the nucleus accumbens of HR. The fact that LR are
marked by a relatively small storage pool containing low
amounts of VMAT, whereas HR are marked by a relatively
large storage pool containing high amounts of VMAT may
well explain why COC-treated LR are more vulnerable to the
dopamine depleting effects of RES than COC-treated HR.
Although it is likely that several mechanisms contribute to
individual differences in the sensitivity to COC, the results of
the present study indicate that HR are more sensitive to COC
than LR because COC can release more dopamine from
accumbal storage vesicles in HR than in LR. Given that this
release of vesicular dopamine may be mediated by dopamine
re-uptake transporters, it is hypothesized that the individual
differences in the COC-induced dopamine increase in HR
and LR are due to a combination of individual differences in
both dopamine re-uptake (Chefer et al. 2003) and vesicular
dopamine release (present study).
Impact
The present ﬁndings open the intriguing possibility that
drugs that deplete dopaminergic storage vesicles of the
mesolimbic system (e.g. RES, Ro 4-1284, and tetrabenazine)
might become the drugs of choice for the treatment of COC
abuse. Interestingly, recent clinical screening trials on the
effects of RES in COC-addicted subjects have already
revealed promising results in this respect (Gorelick et al.
2004; Berger et al. 2005). RES-like agents have also been
found to be effective in the treatment of hyperkinetic
movements disorders like Huntington’s chorea (Huntington
study group 2006; Kenney and Jankovic 2006). These results
suggest that hyperkinesia may, at least in part, be mediated
by dopamine derived from storage vesicles.
In addition to the effects of COC, the effects of
methylphenidate (Ritalin) are also known to depend on
RES-sensitive storage pools (Scheel-Kruger 1971; Chiueh
and Moore 1975; Braestrup 1977; McMillen et al. 1980;
McMillen 1983; Butcher et al. 1991). Methylphenidate is
used to treat patients suffering from attention deﬁcit hyper-
activity disorder (ADHD). Studies in ADHD patients have
revealed large individual differences in the clinical response
to methylphenidate (Volkow et al. 2002; Volkow and
Swanson 2003). Given that HR and LR differ in the size
of the storage pools that are affected by these drugs, HR and
LR may well be a used as an animal model to study the
individual-speciﬁc variability in the treatment of ADHD
(Wooters et al. 2006).
Finally, vesicular uptake is suggested to protect a neuron
against the toxic effects of high levels of cytoplasmatic
dopamine (Truong et al. 2003, 2004). In this respect, it is
important to note that HR, which are marked by a large
number of VMAT, are less sensitive to the neurotoxic effects
of 6-hydroxydopamine than LR, which are marked by a
small number of VMAT (van Oosten and Cools 2002).
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